TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06638450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)
Description: DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Minimal Acupuncture Stimulation (MAS)
Description: MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59). Electrical stimulation will be only performed on bilateral Tongtian (BL07).
Study: NCT05801887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave device
Description: Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No ESWT
Description: the osteoblast like cells are not exposed to shockwaves
Study: NCT06225349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Microencapsulated Magnesium
Description: Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Magnesium Oxide
Description: Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Magnesium Citrate
Description: Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Magnesium Bisglycinate
Description: Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
Study: NCT06222684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
Study: NCT05952596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HepB-IPV-Hib vaccine
Description: Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HepB-IPV-Hib vaccine
Description: Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
Study: NCT04710602

Intervention type: PROCEDURE
Intervention: Minimally invasive surgical fixation of unstable rib cage
Description: Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).

Intervention type: PROCEDURE
Intervention: Large incision surgical fixation of unstable rib cage.
Description: Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
Study: NCT06177522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 1200mg，i.v. , q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: 125 mg/m2, i.v.,d1,d8, q3w
Study: NCT04744428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Parent Navigators
Description: The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer mentoring
Description: Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
Study: NCT04923139

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Dosage at the discretion of the treating physician
Study: NCT06533527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: GLP1 medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: GLP1/GIP medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP1 medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: GLP1 Medication
Study: NCT05824858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.
Study: NCT05922631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation
Description: ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: low tidal volume
Description: The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
Study: NCT06319248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects will receive standard of care for sepsis treatment.
Study: NCT06227520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decellularized dermal matrix
Description: Application of Wound bed
Study: NCT06103240

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lacticaseibacillus rhamnosus LRa05
Description: Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lacticaseibacillus rhamnosus LRa05
Description: Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
Study: NCT06527677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANT3310
Description: ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
Study: NCT06565130

Intervention type: OTHER
Group type: OTHER
Intervention: Attention skills training
Description: Attention skills program planned with occupational therapy principles
Study: NCT06177522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.0 g/m2, i.v.,d1, d8, q3w
Study: NCT06256900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation
Description: FCV mode during robot-assisted laparoscopic surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-controlled ventilation
Description: PCVmode during robot-assisted laparoscopic surgery
Study: NCT05488483

Intervention type: DIAGNOSTIC_TEST
Intervention: Multispectral Optoacoustic Tomography Imaging
Description: Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
Study: NCT05218707

Intervention type: OTHER
Intervention: GUEDEL Airway
Description: GUEDEL Airway of size '000,00,0,' and '1' will be used.
Study: NCT05389072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control contact lens
Description: control CRT lens
Study: NCT04886531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (L) or Anastrozole (A)
Description: L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
Study: NCT06365463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
Study: NCT05562934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT06303427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Description: The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Description: The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
Study: NCT06010914

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study: NCT05473715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept(BAY86-5321, Eylea)
Description: 2mg, intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept(BAY86-5321, Eylea)
Description: 2mg, intravitreal (IVT) injection
Study: NCT06323161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT06561165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard HD-tDCS intervention
Description: Participants will have three sessions along with behavioral assessments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal network targeted HD-tDCS intervention
Description: Participants will have three sessions along with behavioral assessments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will have an MRI before or after having HD-tDCS intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will have an MRI before or after having HD-tDCS intervention.
Study: NCT06409260

Intervention type: OTHER
Group type: OTHER
Intervention: Acceleromyography (AMG)
Description: Philips IntelliVue NMT Module

Intervention type: OTHER
Group type: OTHER
Intervention: Acceleromyography (AMG)
Description: Philips IntelliVue NMT Module
Study: NCT05465941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated SN-38 Conjugate PLX038
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT06409260

Intervention type: OTHER
Group type: OTHER
Intervention: Electromyography (EMG)
Description: Senzime TetraGraph

Intervention type: OTHER
Group type: OTHER
Intervention: Electromyography (EMG)
Description: Senzime TetraGraph
Study: NCT06637306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
Study: NCT04717466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 300mg subcutaneous injection
Study: NCT06637579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: universal exercise unit therapy with task oriented strength training
Description: Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training for gross motor functioning
Description: Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
Study: NCT06233591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10 (Liposomal Tacrolimus)
Description: Liposomal oral rinse formulation of Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10 (Liposomal Tacrolimus)
Description: Liposomal oral rinse formulation of Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10 (Liposomal Tacrolimus)
Description: Liposomal oral rinse formulation of Tacrolimus
Study: NCT06642025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Injection
Description: Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage.
Study: NCT06637657

Intervention type: OTHER
Intervention: No intervention (observational study)
Description: No intervention, only guideline implementation (observational study)

Intervention type: OTHER
Intervention: No intervention (observational study)
Description: No intervention, only guideline implementation (observational study)
Study: NCT06638528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking apnea at High Lung Volume
Description: Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking normal breathing
Description: Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
Study: NCT06644703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
Study: NCT06644365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupresure mat
Description: The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic mat
Description: The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
Study: NCT06645431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Intake
Description: Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.